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Brendan Doyle, MD,* Noel Caplice, MD, PHD†
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The concept that neovascularization of the vessel wall may play a fundamental role in the pathophysiology of
atherosclerosis was proposed more than a century ago. In recent years, supportive experimental evidence for
this hypothesis (such as the finding that neointimal microvessels may increase delivery of cellular and soluble
lesion components to the vessel wall) has been underscored by clinical studies associating plaque angiogenesis
with more rapidly progressive high-grade disease. Attention has also focused on a possible role for microvessel-
derived intraplaque hemorrhage in the development of acute lesion instability. The interest of clinicians in this
phenomenon has been spurred by the potential to target vessel wall neovascularization with angiogenesis inhibi-
tors, a therapeutic approach that has been associated with impressive reductions in plaque progression in ani-
mal models of vascular disease. The rationale for pursuing an “antiangiogenic” strategy in the treatment of pa-
tients with vascular disease, and a framework for further preclinical evaluation of such therapy, is presented
here. (J Am Coll Cardiol 2007;49:2073–80) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.089m
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tccumulating evidence has linked plaque angiogenesis with
rogressive atherosclerotic disease and the development of
cute lesion instability. However, no consensus has yet
merged as to whether a true causal association exists. The
mplications of this debate for clinical practice are signifi-
ant. Burgeoning interest in proangiogenic gene and cell
herapies is tempered by concerns regarding the potential
or these therapies to accelerate and/or destabilize athero-
clerotic disease. In contrast, the availability of a growing
umber of “antiangiogenic” agents holds the potential for a
ew therapeutic paradigm in vascular disease, targeting
laque microvasculature with the aim of slowing plaque
rowth and promoting plaque stability. This approach has
lready shown promising results in cancer therapy and in
ther conditions such as macular degeneration and rheuma-
oid arthritis, where a role for angiogenesis in disease
rogression is increasingly recognized. As our ability to
odulate angiogenesis in vivo expands, these therapeutic
pportunities and potential pitfalls merit careful consider-
tion in the context of the overall debate surrounding vessel
all neovascularization and atherosclerosis.
In this review we examine the pathophysiologic and
xperimental basis for therapeutic targeting of the plaque
rom the *Division of Cardiovascular Diseases, Molecular Medicine Program, Mayo
linic, Rochester, Minnesota; and †Centre for Research in Vascular Biology,
iosciences Institute, University College Cork, Cork, Ireland.d
Manuscript received May 24, 2006; revised manuscript received December 12,
006, accepted January 18, 2007.icrovasculature and present a framework for future pre-
linical investigation as this treatment strategy evolves.
hroughout, the terms “antiangiogenic” and “proangio-
enic” (or similar) are used in relation to agents that are
onsidered to have demonstrated such activity in vitro
nd/or in vivo. However, it should be acknowledged at the
utset that our understanding of the regulators of neovas-
ularization in vivo remains incomplete and, indeed, that a
umber of putative molecules have failed to perform as
xpected in clinical trials (1,2).
eovascularization of Atherosclerotic Arteries
asa vasorum-derived microvessels do not extend to the
ntima of normal arteries, penetrating only the adventitia
nd outer media (3). Diffusion of oxygen and other nutrients
s limited to 100 m from the lumen of the blood vessel,
hich in normal arteries is adequate to nourish the inner
edia and intimal layers. As vessel wall thickness increases
n the setting of vascular disease, proliferation of the vasa
asorum and intimal neovascularization is observed.
Accumulating histopathologic data associates plaque an-
iogenesis with more rapidly progressive and unstable vas-
ular disease (4). Briefly, these studies confirm intimal
eovascularization to be an almost ubiquitous feature of
therosclerotic disease, correlating with both histologic
rade (5,6) and symptoms (7). The majority of microvessels
rise from the adventitial vasa vasorum (8,9) and rarely from
he luminal surface of the parent artery (8). Microvessel
ensity is greatest in lesions with marked macrophage
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(10), in lipid-rich lesions (6,11),
and in thin-cap atheroma (10),
all features of so-called vulnerable
plaque (12). Rupture is most fre-
quently identified at the shoulder
of such lesions, and increased den-
sity of plaque microvessels has
een identified at this site (10,13). Finally, the presence
f angiogenesis at the base of the plaque has been
ndependently correlated with plaque rupture, underscor-
ng the potential for a direct contributory role of neovas-
ularization in this process (10).
echanisms of Vessel Wall Neovascularization
he process of new blood vessel growth is frequently
eferred to as angiogenesis. More recently, use of this term
as been narrowed to define a process characterized by
xtension of an existing vascular bed by sprouting of new
apillaries from postcapillary venules. Therefore, in this
aper, the term “angiogenesis” does not encompass the
ntire spectrum of events that can result in new blood vessel
evelopment, such as arteriogenesis (large-caliber collateral
essel formation) or vasculogenesis (de novo formation of
ew blood vessels by in situ differentiation of primitive stem
ells). Initial steps in angiogenesis include an increase in
ascular permeability and proteolytic degradation of the
urrounding extracellular matrix. This is followed by che-
otactic migration and proliferation of endothelial cells,
ormation of a lumen, and functional maturation of the
ewly formed capillary by tightening of interendothelial cell
unctions.
The molecular mechanisms underlying vessel wall angio-
enesis in vascular disease are now being elucidated (Fig. 1).
ypoxia is one of the most potent stimuli for angiogenesis,
nd zones of hypoxia are present within thickened athero-
clerotic plaque (14). Hypoxia-induced neoangiogenesis is
egulated by hypoxia inducible factor-1 (HIF-1), a het-
rodimeric transcription factor composed of a HIF-1-alpha
nd HIF-1-beta subunit. In order to respond rapidly to
ypoxia, cells continuously synthesize, ubiquitinate, and
egrade HIF-1-alpha protein under normoxic conditions.
nder hypoxic conditions, such degradation is inhibited,
esulting in accumulation of the protein, dimerization with
IF-1-beta, binding to hypoxia-responsive elements within
arget genes, and activation of transcription via recruitment
f the coactivators p300 and CBP (15). The expression of
ore than 40 genes is known to be activated at the
ranscriptional level by HIF-1, including those responsible
or production of nitric oxide synthase and vascular endo-
helial growth factor (VEGF) (15). The initial step in
ngiogenesis involves nitric-oxide-mediated vasodilation.
ascular permeability subsequently increases in response to
EGF, allowing extravasation of plasma proteins that lay
Abbreviations
and Acronyms
HIF  hypoxia inducible
factor
VEGF  vascular endothelial
growth factorown a provisional scaffold for migrating endothelial cells e1). Thus, it appears likely that hypoxia within the plaque
ore is an important trigger of proangiogenic activity in
stablished vascular lesions that exhibit significant neointimal
hickening.
A role for vessel wall hypoxia and plaque angiogenesis in
arly atherosclerotic disease has been studied, but not yet
rmly established. Up-regulation of proangiogenic growth
actors (including VEGF) within the vessel wall may pre-
ede intimal thickening (4), and, indeed, coronary neovas-
ularization in hypercholesterolemic swine precedes the
evelopment of endothelial dysfunction (16). Furthermore,
xperimental occlusion of adventitial vasa vasorum may lead
o intimal lesions that resemble atherosclerosis (17). To-
ether, these hypothesis-generating data suggest that im-
aired perfusion of the vessel wall (owing to adventitial
icrovascular dysfunction) may be an alternative mecha-
ism leading to vessel wall hypoxia, even in the absence of
eointimal thickening, and may be relevant in the initiation
f plaque development. Further pathophysiologic insights in
his area have the potential to generate valuable new
oncepts of early vascular disease, with possibilities for
herapeutic development.
Adding to the complexity of this biology, hypoxia-
ndependent pathways for modulation of angiogenesis
ithin the vessel wall have also been identified. For exam-
le, hypertension may induce vessel wall neovascularization
y hypoxic activation of the HIF-1 system (owing to medial
hickening) (18), but direct induction of VEGF expression
y smooth muscle cells exposed to stretch has also been
emonstrated (19). Oxidative stress and nicotine may mod-
late growth factor gene expression in vascular cells inde-
endent of the presence of hypoxia (20–24).
The relative importance of hypoxia-dependent and
independent pathways in proangiogenic growth factor gene
xpression in vascular disease has yet to be defined. How-
ver, evidence that downstream mediators of angiogenesis
re active in the diseased vessel wall is not in doubt; growth
actors such as VEGF, hepatocyte growth factor, and
latelet-derived growth factor are abundantly expressed
ithin atherosclerotic lesions (5,25–30). Recognized sources
f these growth factors include intraplaque cells (such as
henotypically modified smooth muscle cells and inflamma-
ory cells) and the extracellular matrix (31–36) (Fig. 1).
mportantly, the distribution of such growth factors has
een correlated spatially and quantitatively with vessel wall
eovascularization (5,25). Moreover, early administration
f VEGF or fibroblast growth factor in experimental
odels of vascular disease has been associated with
ccelerated neovascularization of the vessel wall and more
ggressive lesion development (37–39). Collectively,
hese data support a role for proangiogenic growth factor
xpression in plaque progression.
Increased expression of proangiogenic growth factors may
ot, however, be sufficient to induce angiogenesis in isola-
ion. This is because of the countervailing influence of
ndogenous inhibitors of angiogenesis such as the throm-
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May 29, 2007:2073–80 Plaque Angiogenesisospondins (40), platelet factor-4 (41), endostatin (42), and
allistatin (43) (Fig. 1). The competitive balance between
hese agonists and inhibitors has been the subject of intense
tudy in tumor biology. Less is known at present about their
ole in vascular disease, although experimental animal mod-
ls support a role for endogenous systems of angiogenesis
nhibition as a regulatory mechanism in plaque growth. For
xample, deficiency of collagen XVIII and its proteolytically
eleased endostatin fragment (normally found in vascular
asement membranes and the walls of major blood vessels)
s associated with enhanced intimal neovascularization and
Figure 1 Mechanisms of Vessel Wall Neovascularization in Ath
Increased proangiogenic activity, which may be accompanied by reduced endogeno
cularization. FGF  fibroblast growth factors; HGF  hepatocyte growth factor; PDG
thelial growth factor. Copyrighted and used with permission of Mayo Foundation foore aggressive atheroma formation (44). Furthermore, ningle-nucleotide polymorphisms of thrombospondin-1, -2,
nd -4, which are associated with reduced plasma levels of
hrombospondin, are also associated with increased risk of
remature myocardial infarction (45). Most notably, evi-
ence that endogenous inhibitors of angiogenesis can be
own-regulated in vivo is now emerging (46). Notwith-
tanding these intriguing findings, there is as yet no con-
lusive evidence from human studies to support dysregula-
ion of an “angiogenic switch” within the vessel wall
haracterized by increased proangiogenic growth factor
ctivity and accompanied by down-regulation of endoge-
lerosis
ibition of angiogenesis, results in vasa vasorum proliferation and intimal neovas-
latelet-derived growth factor; SMC  smooth muscle cell; VEGF vascular endo-
ical Education and Research.erosc
us inh
F  p
r Medous inhibitors.
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ngiogenesis in Vascular Disease
onduits for cellular and soluble lesion components. A
undamental paradigm of vascular disease has for many
ears presumed the artery luminal endothelium to be the key
ortal for cellular and soluble lesion components (such as
ipid, cytokines, and growth factors) found in atherosclerotic
laque (47). However, it is plausible that intraplaque vessels
ay also function as an important endothelial interface in
he recruitment of these lesion components. This concept is
ore understandable when one considers the significantly
reater endothelial surface area and lower blood flow veloc-
ties through these microvessels when compared to that of
he macroarterial system, albeit that the absolute level of
Figure 2 Role of Vessel Wall Neovascularization in Plaque Grow
Possible roles for microvessels in disease progression include the supply of cellul
delivery of metabolic substrates to the plaque core. ICAM  intercellular adhesion
Copyrighted and used with permission of Mayo Foundation for Medical Education alood flow through this microvasculature is still uncertain. ctudies by Heistad et al. (48) have raised an interesting
hysiologic dilemma in this regard, whereby intraplaque
ydrostatic pressure estimated around 100 mm Hg did not
ppear to significantly compromise flow through this circuit
rom adventitial arteries, which are likely to exhibit a mean
ntravascular pressure of no more than 40 mm Hg. Never-
heless, increased solute delivery to the vessel wall by vasa
asorum in hypercholesterolemia has been demonstrated
49), lending further support to a conceptual framework
hereby plaque microvessels might transport lipid as well as
ells to the vessel wall. Metabolic substrates required for
ngoing smooth muscle and inflammatory cell activity
ight also be provided, permitting growth beyond the
hreshold whereby diffusion from the artery lumen is insuffi-
soluble lesion components, enhancement of intraplaque gas exchange, and
ule; LDL  low-density lipoprotein; VCAM  vascular cell adhesion molecule.
search.th
ar and
molec
nd Reient to meet the metabolic demands of the plaque (Fig. 2).
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ole for microvessels within the artery wall has been ex-
remely challenging, particularly with regard to a role in cell
elivery to the plaque. The spatial and quantitative correla-
ion of intraplaque vessels with focal collections of inflam-
atory cells could occur because these cells stimulate
ngiogenesis and/or because the plaque microvasculature is
articularly active in the delivery and recruitment of inflam-
atory cells (50) (Fig. 2). In support of the latter interpre-
ation is the finding that expression of leukocyte adhesion
olecules is more prevalent on intimal microvascular endo-
helium than on arterial luminal endothelium and that the
resence of these adhesion molecules on neovessels is
trongly associated with increased leukocyte accumulation
11,51). Moreover, use of angiostatin in a murine model of
therosclerosis was found to reduce plaque microvessel
ensity and inhibit atherosclerosis development (50) and
ead to reduced plaque macrophage content (50).
The latter study has been criticized on the basis that
ouse aortas are relatively small with a thin media and may
ot accurately model human vascular disease, where the
imit of diffusion (approximately 100 m) is likely to be of
reater functional relevance (52). Only a minority of lesions
n this study exhibited neovascularization (50), in keeping
ith a lesser role for vessel wall neovascularization in murine
therosclerosis. Other beneficial effects of angiostatin may
ave accounted for the impressive reductions in disease
rogression that were observed, but they should not detract
rom the overall findings of this study. Validation of this
herapeutic approach in large animal models will be of
Figure 3 Intraplaque Hemorrhage
Plaque neovessels are of relatively large caliber and poorly invested with smooth m
ing enzymes released by inflammatory cells. Intraplaque hemorrhage from these v
metalloproteinases. Copyrighted and used with permission of Mayo Foundation formmense interest as the field moves forward. dntraplaque Hemorrhage
ntraplaque hemorrhage is increasingly recognized as a key
echanism through which atherosclerotic plaque may ex-
and rapidly and/or rupture (53) (Fig. 3). Plaque neovessels
re thin walled, usually without investment by smooth
uscle cells or pericytes, and are often of quite large caliber
hen compared to normal capillaries (3). This fragile
tructure could reasonably be regarded as sufficient in itself
o render these vessels prone to hemorrhage, and indeed, the
resence of intraplaque hematoma has been colocalized with
hese vessels and not intimal disruption, implicating them
and not the artery lumen) as the source of such hemorrhage
53). The added presence of matrix-degrading enzymes
roduced by macrophages and mast cells, which are fre-
uently found in close proximity to these fragile microves-
els, may further exacerbate their tendency to rupture (53).
xperimental study of the role of intraplaque hemorrhage in
laque rupture has in the past been hampered by a lack of
uitable animal models, although a recently described mu-
ine model of plaque rupture may provide new opportunities
n this regard (54).
ther Proatherogenic Mechanisms
xpression of matrix metalloproteinases is increased in
ulnerable regions of human atherosclerotic plaque (55) and
s a mechanism that may contribute to the development of
laque rupture. The finding of high neovascularization
ensities in these same unstable plaque regions suggests that
ngiogenesis may be an important source of this matrix-
cells, a structural weakness that may be further compromised by matrix degrad-
may contribute to plaque instability and/or lesion expansion. MMPs  matrix
al Education and Research.uscle
essels
Medicegrading activity (56). Increased vasoreactivity has also
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Plaque Angiogenesis May 29, 2007:2073–80een observed in diseased coronary segments and is a factor
hat has been implicated in the genesis of acute coronary
yndromes. It has been suggested (49) that increased vessel
all blood supply related to plaque angiogenesis in these
egments may influence the predilection to spasm by pro-
iding higher local concentrations of circulating cat-
cholamines and other vasoactive agents (57). The role of
oronary vascular tone in the etiology of microvessel rupture
s unknown but may be another mechanism through which
oronary spasm may contribute to the development of acute
oronary syndromes.
ntiangiogenic Therapy for Atherosclerosis
onsiderable interest is focusing on a treatment approach
argeting inhibition of microvessel formation and/or func-
ion within atherosclerotic plaque. More than 300 potential
nhibitors of angiogenesis have been identified, of which 80
re currently being tested in clinical trials (58). Their
echanisms of action are varied, affecting aspects of angio-
enesis such as endothelial cell proliferation, the availability
r production of endothelial cell growth factors, the signal-
ng of tyrosine kinase receptors on endothelial cells, and the
ctivity of metalloprotease enzymes. Although significant
ifferences in efficacy between agents may not be apparent in
heterogeneous patient group, it is possible that subpopu-
ations such as diabetics may ultimately benefit from tailored
herapy that takes account of specific signaling or other
olecular defects of angiogenesis known to be more prev-
lent in these patients (59). Combination therapy using 2 or
ore inhibitors with differing mechanisms of action may
lso prove necessary to achieve maximal therapeutic effect.
he first antiangiogenesis clinical trials in cancer patients
id not live up to their high expectations, in part because the
dvanced tumors being treated had already activated various
athways that allowed them to easily override the angio-
enic restrictions of a single inhibitor (60). It would be
rudent to anticipate similar obstacles in the antiangiogenic
reatment of atherosclerosis.
That angiogenesis inhibitors may favorably influence
laque microvessel function by inducing functional matura-
ion of these vessels is another intriguing possibility (61).
educed vessel “leakiness” in response to antiangiogenic
herapy has been demonstrated in cancer studies, enhancing
hemotherapeutic drug delivery to the tumor and decreasing
he risk of metastasis (62). Similar effects on plaque micro-
ascular integrity could play an important role in reducing
isk of intraplaque hemorrhage. Microvascular “maturation”
ight also facilitate the development of therapies targeting
laque regression. For instance, improved microvascular
xchange might facilitate high-density lipoprotein cholesterol-
ediated “reverse cholesterol transport” from lesions or the
rafficking of monocyte-derived cells from atherosclerotic
laque. The latter has recently been documented to occur
uring lesion regression (63). Improved delivery of novel
gents that influence plaque biology (targeting the inflam- watory milieu or the function of phenotypically modified
ascular smooth muscle cells) may also be a favorable conse-
uence of microvascular maturation, analogous to the synergy
hat has been observed between antiangiogenic and cytotoxic
herapies in cancer (64).
An ability to optimize the choice and dose of angiogen-
sis inhibitor using reliable surrogate markers of efficacy may
e critical to success in the clinic. Optimal dosing of
ssorted protein fragment statins, for example, is likely to be
hallenging, given that such fragments may already be
ariably expressed within the proteolytic environment of the
laque. Novel circulating markers of angiogenesis show
romise (65), as do increasingly sophisticated imaging
echniques (such as molecular imaging using magnetic
esonance imaging) that may directly quantitate vessel wall
eovascularization in vivo (66,67). Detection of changes in
rtery wall oxygenation may be possible using positron
mission tomography with 18-fluoromisonidazole or mag-
etic resonance imaging (64). High-resolution imaging can
lso identify complications of plaque angiogenesis such as
ntraplaque hemorrhage (68), a potentially valuable index of
herapeutic efficacy. Ultimately, such tools may not only
ssist in selection and titration of antiangiogenic therapy,
ut might also identify patients most likely to benefit in the
rst instance.
The greatest concern regarding use of angiogenesis in-
ibitors in atherosclerosis is undoubtedly the potential for
hese agents to aggravate preexisting end-organ ischemia.
iming of therapy may be crucial, with no adverse effect of
ngiogenesis inhibitors on collateral development when
reatment was delayed for some time after vascular occlusion
69). Other concerns include the possibility that microvessel
maturation” may in fact promote disease progression by
mproving delivery of oxygen and nutrients to the vessel wall
64). Interestingly, experimental and clinical studies in
umor biology do not indicate that lesion growth accelerates
uring antiangiogenic monotherapy. The reasons for this
re poorly understood but may suggest a predominance of
icrovessel regression over microvessel maturation as the
echanism of therapeutic benefit (64).
On a final cautionary note, it should be recognized that
ur understanding of these complex agents and their
ffects in vivo, and in a variety of disease settings, is still
t a very early stage. Recent clinical experience with
yclooxygenase-2 inhibitors, in particular, has emphasized
hat although some angiogenesis inhibitors may prove to
ave a protective function in the cardiovascular system,
hese findings may not pertain to all agents with antiangio-
enesis activity (70). Already, certain agents have been
ssociated with the development of a prothrombotic state
71) and hypertension (72). Direct cardiotoxicity leading to
evere congestive heart failure has recently been described as
rare complication of imatinib therapy (73). Together,
hese data underscore an absolute requirement for rigorous
xperimental evaluation of this treatment paradigm before
e can begin to consider the possibility of clinical trials.
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